Inhalation of urokinase-type plasminogen activator reduces airway remodeling in a murine asthma model

被引:31
|
作者
Kuramoto, Emi
Nishiuma, Teruaki
Kobayashi, Kazuyuki
Yamamoto, Masatsugu
Kono, Yuko
Funada, Yasuhiro
Kotani, Yoshikazu
Sisson, Thomas H. [2 ]
Simon, Richard H. [2 ]
Nishimura, Yoshihiro [1 ]
机构
[1] Kobe Univ, Grad Sch Med, Dept Internal Med, Div Resp Med,Chuo Ku, Kobe, Hyogo 6500017, Japan
[2] Univ Michigan, Sch Med, Dept Internal Med, Div Pulm & Crit Care Med, Ann Arbor, MI USA
关键词
urokinase; plasmin; bronchial asthma; subepithelial fibrosis; HEPATOCYTE GROWTH-FACTOR; INDUCED PULMONARY-FIBROSIS; INDUCED LUNG FIBROSIS; TGF-BETA; INFLAMMATION; INHIBITOR-1; EXPRESSION; COLLAGEN; MICE; ACCUMULATION;
D O I
10.1152/ajplung.90434.2008
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Kuramoto E, Nishiuma T, Kobayashi K, Yamamoto M, Kono Y, Funada Y, Kotani Y, Sisson TH, Simon RH, Nishimura Y. Inhalation of urokinase-type plasminogen activator reduces airway remodeling in a murine asthma model. Am J Physiol Lung Cell Mol Physiol 296: L337-L346, 2009. First published December 19, 2008; doi: 10.1152/ajplung.90434.2008.-The airway remodeling that occurs in asthma is characterized by an excess of extracellular matrix deposition in the submucosa, hyperplasia/hypertrophy of smooth muscle, goblet cell metaplasia, and accumulation of fibroblasts/myofibroblasts. he urokinase-type plasminogen activator (uPA)/plasmin system participates in pericellular proteolysis and is capable of directly degrading matrix components, activating latent proteinases, and activating growth factors. In a mouse ovalbumin (OVA) asthma model, we increased plasminogen activator activity in the lung by administering exogenous uPA or by using mice genetically deficient in the uPA inhibitor plasminogen activator inhibitor-1 (PAI-1) to assess the role of this system in asthma pathogenesis. After intraperitoneal OVA sensitization, mice inhaled OVA plus uPA (500 IU/mouse) or saline by ultrasonic nebulization for 3 wk. When studied 24 h after the final exposure, the groups with upregulated plasmin activity had significantly reduced subepithelial fibrosis within the airway walls and had decreased airway hyperresponsiveness (AHR) to methacholine. Morphometric analysis showed that subepithelial wall thickening of the bronchi (subepithelial area ratio) was also reduced, as were collagen and alpha-smooth muscle actin. Upregulation of plasmin activity also increased the level of hepatocyte growth factor activity in bronchoalveolar lavage fluid, whereas the release of transforming growth factor-beta was decreased. The administration of uPA 1 wk after the last OVA inhalation also significantly reduced lung hydroxyproline content and AHR. These results show that enhancing uPA/plasmin activity lessens the airway remodeling in a murine asthma model.
引用
收藏
页码:L337 / L346
页数:10
相关论文
共 50 条
  • [41] Urokinase-Type Plasminogen Activator Inhibits Efferocytosis of Neutrophils
    Yang, Yanping
    Friggeri, Arnaud
    Banerjee, Sami
    Bdeir, Khalil
    Cines, Douglas B.
    Liu, Gang
    Abraham, Edward
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2010, 182 (12) : 1516 - 1523
  • [42] Properties of the Urokinase-Type Plasminogen Activator Modified with Phenylglyoxal
    L. I. Moukhametova
    R. B. Aisina
    G. Yu. Lomakina
    S. D. Varfolomeev
    Russian Journal of Bioorganic Chemistry, 2002, 28 : 278 - 283
  • [43] Urokinase-type plasminogen activator in human gliomas in vitro
    Gillespie, J
    McCormick, D
    NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 1996, 22 (05) : 454 - 454
  • [44] Role of urokinase-type plasminogen activator in local immunotherapy
    Takeda, T
    Ito, Y
    Wakasugi, E
    Kobayashi, T
    Monden, M
    ONCOLOGY REPORTS, 1998, 5 (02) : 329 - 333
  • [45] The urokinase-type plasminogen activator and its receptor in cancer
    Rosenberg, S
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 34, 1999, 34 : 121 - 128
  • [46] Inhibitors of the protease domain of urokinase-type plasminogen activator
    Rockway, TW
    Nienaber, V
    Giranda, VL
    CURRENT PHARMACEUTICAL DESIGN, 2002, 8 (28) : 2541 - 2558
  • [47] The Urokinase-type Plasminogen Activator and the Generation of Inhibitors of Urokinase Activity and Signaling
    Carriero, Maria Vincenza
    Stoppelli, Maria Patrizia
    CURRENT PHARMACEUTICAL DESIGN, 2011, 17 (19) : 1944 - 1961
  • [48] The Light Chain Allosterically Enhances the Protease Activity of Murine Urokinase-Type Plasminogen Activator
    Torres-Paris, Constanza
    Song, Harriet J.
    Engelberger, Felipe
    Ramirez-Sarmiento, Cesar A.
    Komives, Elizabeth A.
    BIOCHEMISTRY, 2024, 63 (11) : 1434 - 1444
  • [49] Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: Correlation with tumor associated macrophage and prognosis
    Ohba, K
    Miyata, Y
    Kanda, S
    Koga, S
    Hayashi, T
    Kanetake, H
    JOURNAL OF UROLOGY, 2005, 174 (02): : 461 - 465
  • [50] UROKINASE-TYPE PLASMINOGEN-ACTIVATOR, UROKINASE-TYPE PLASMINOGEN-ACTIVATOR RECEPTOR AND PLASMINOGEN-ACTIVATOR INHIBITOR-1 I IN BREAST-CANCER CELLS
    WAJIMA, T
    DEGEN, D
    ORIZ, V
    VONHOFFOLIN, DD
    THROMBOSIS AND HAEMOSTASIS, 1995, 73 (06) : 1284 - 1284